Less than a tenth of patients who could benefit from obesity jabs including Wegovy can access them, states the WHO as it releases its initial recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The latest guidance affirms that excess weight is a chronic disease that can be treated with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major hurdles to universal access to the treatments that can help people shift considerable weight, explains the body.
GLP-1 Therapy Scarcity
Even in the present most favorable case, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation encourages nations and manufacturers to increase access, via approaches including licensing agreements.
A patent on semaglutide – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so people eat less.
Patients usually begin shedding pounds after several weeks of commencing the weekly injections.
Research points to people may regain a significant portion a year later of discontinuing the medication, because their usual food cravings come back.
Being above a healthy weight raises your chance for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity affects individuals in every country and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
